RSV

Not too late to vaccinate

Retrieved on: 
Friday, March 1, 2024

The recommendation acknowledges the increased risk of severe disease from COVID-19 in older adults, along with the currently available data on vaccine effectiveness.

Key Points: 
  • The recommendation acknowledges the increased risk of severe disease from COVID-19 in older adults, along with the currently available data on vaccine effectiveness.
  • It takes two weeks after vaccination for antibodies to develop in the body and provide protection against the viruses.
  • Adults 60 or older should talk to their health care provider to determine if the RSV vaccine is right for them.
  • The mission of the Missouri Department of Health and Senior Services (DHSS): To promote health and safety through prevention, collaboration, education, innovation and response.

Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19

Retrieved on: 
Wednesday, February 21, 2024

BOSTON, MASSACHUSETTS, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, announced that the first patients have been treated with ProLectin-M in its dose optimization trial. ProLectin-M is intended to become a first line treatment for standard risk COVID-19 patients, but based on the broad-spectrum in vitro discovery could easily expand to upper respiratory tract infections. Following this dose optimization trial, Bioxytran intends to use the trial data to inform the design of the Phase 3 registrational trial in India, while also adhering to the FDA’s request for additional data.

Key Points: 
  • Following this dose optimization trial, Bioxytran intends to use the trial data to inform the design of the Phase 3 registrational trial in India, while also adhering to the FDA’s request for additional data.
  • The multi-center clinical trial in India will be a randomized double-blind placebo-controlled trial and is set to enroll 40 patients.
  • “After we complete the dose optimization trial, the next regulatory milestone is a registrational trial,” said Dr. Leslie Ajayi, Bioxytran’s medical director.
  • “We are on the cusp of completing a clinical trial of standard risk patient that contracted COVID-19.

Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults

Retrieved on: 
Thursday, February 29, 2024

Pfizer Inc. (NYSE: PFE) today announced top-line ABRYSVO® vaccine efficacy and safety data for respiratory syncytial virus (RSV) in adults 60 years of age and older following a second season in the Northern and Southern Hemispheres from the ongoing pivotal Phase 3 clinical trial ( NCT05035212 ) RENOIR (RSV vaccine Efficacy study iN Older adults Immunized against RSV disease).

Key Points: 
  • Pfizer Inc. (NYSE: PFE) today announced top-line ABRYSVO® vaccine efficacy and safety data for respiratory syncytial virus (RSV) in adults 60 years of age and older following a second season in the Northern and Southern Hemispheres from the ongoing pivotal Phase 3 clinical trial ( NCT05035212 ) RENOIR (RSV vaccine Efficacy study iN Older adults Immunized against RSV disease).
  • Vaccine efficacy against RSV-associated lower respiratory tract disease (LRTD), defined by three or more symptoms, after disease surveillance in season two was 77.8% (95.0% CI: 51.4, 91.1); vaccine efficacy following season one was 88.9% (95.0% CI: 53.6%, 98.7%)1, which demonstrates durable efficacy after two seasons.
  • Consistent vaccine efficacy was demonstrated for both RSV A and RSV B after season two with vaccine efficacy against each subtype of ≥80% for LRTD with three or more symptoms.
  • No new adverse events were reported through the second RSV season beyond what was reported by subjects in the clinical trial during the first season.

MEDI8897 (Nirsevimab): An Investigational Long-Acting Antibody that Protects all Infants through their First RSV Season with a Single Dose - Market Size, Forecasts, and Market Insight 2019-2032 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024

The report provides comprehensive insights about MEDI8897 for Respiratory syncytial virus (RSV) in the seven major markets.

Key Points: 
  • The report provides comprehensive insights about MEDI8897 for Respiratory syncytial virus (RSV) in the seven major markets.
  • MEDI8897 (Nirsevimab) is an investigational long-acting antibody that protects all infants through their first RSV season with a single dose.
  • Nirsevimab is an immunization that provides direct prophylactic RSV protection to all infants via an antibody to help prevent LRTI caused by RSV.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MEDI8897 in RSV.

IQVIA Publishes its 2023 Environmental, Social and Governance Report

Retrieved on: 
Monday, February 26, 2024

IQVIA™ (NYSE:IQV), has published its 2023 Environmental, Social and Governance (ESG) Report.

Key Points: 
  • IQVIA™ (NYSE:IQV), has published its 2023 Environmental, Social and Governance (ESG) Report.
  • “We are proud that we delivered on our sustainability commitments despite the tumultuous macro-environment we have been operating in.”
    IQVIA’s full 2023 ESG report can be downloaded here .
  • We established our dedicated global public health business in 2023, which now works with more than 75 clients across the globe.
  • For the third year in a row, IQVIA was named the number one most admired company in our category, Healthcare: Pharmacy and Other Services.

Syndromic Multiplex Diagnostic Markets with COVID-19 Impacts, Strategies and Trends, Forecasts and Executive Guides & Customization - Global Forecasts to 2029 - ResearchAndMarkets.com

Retrieved on: 
Monday, February 26, 2024

5.2.3 Infectious Disease is Declining But..

Key Points: 
  • 5.2.3 Infectious Disease is Declining But..
    5.2.5 Economic Growth improves Living Standards.
  • 5.3.3 Syndrome Testing Moving to Big Instruments?
  • 5.4.6 Syndromics drives POCT adoption.
  • 5.4.7 A Big Future for PCR?

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, February 22, 2024

Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
  • Complete 24-week treatment data for 30 participants per regimen is expected in the fourth quarter of 2024.
  • The MARCH Part B trial is ongoing with 48-week end of treatment data expected in the fourth quarter of 2024.
  • Revenues: Total revenues for the quarter ended December 31, 2023 were $16.8 million compared to $49.4 million for the same period in 2022.

Atomic AI Announces Appointments of New Independent Member to its Board of Directors and Additions to the Scientific Advisory Board

Retrieved on: 
Thursday, February 22, 2024

Atomic AI, a biotechnology company fusing cutting-edge machine learning with state-of-the-art structural biology to unlock RNA drug discovery, today announced the appointment of Stuart Peltz, Ph.D. as an independent board member to the Atomic AI Board of Directors, and the additions of Percy Carter, MBA, Ph.D., and Nicholas Meanwell, Ph.D. to their Scientific Advisory Board (SAB).

Key Points: 
  • Atomic AI, a biotechnology company fusing cutting-edge machine learning with state-of-the-art structural biology to unlock RNA drug discovery, today announced the appointment of Stuart Peltz, Ph.D. as an independent board member to the Atomic AI Board of Directors, and the additions of Percy Carter, MBA, Ph.D., and Nicholas Meanwell, Ph.D. to their Scientific Advisory Board (SAB).
  • “We are extremely pleased to have these highly regarded, experienced biotech leaders join in our efforts and believe in our mission,” said Raphael Townshend, Ph.D., Founder and CEO of Atomic AI.
  • Peltz’s experience will help shape our strategy as we endeavor to streamline the discovery and development of novel therapies.
  • “They have demonstrated tremendous progress integrating deep learning foundation models with experimental results to be able to predict and optimize RNA structures to enable rational drug design.

University Medical Devices Raises $1.6 Million in Seed Funding to Launch First-of-its-Kind Nasal Specimen Collection Device for Diagnosing Upper Respiratory Infections

Retrieved on: 
Tuesday, February 20, 2024

University Medical Devices (UMD) today announced the closure of its first round of seed funding.

Key Points: 
  • University Medical Devices (UMD) today announced the closure of its first round of seed funding.
  • Funds are earmarked to advance UMD’s infrastructure, covering regulatory, medical, legal, manufacturing, packaging, sales and marketing.
  • This funding round represents a major step toward UMD achieving profitability and sustainability, with a strong emphasis on bringing its first product – MicroWash – to market.
  • MicroWash plays a pivotal role in addressing the challenges posed by the “tripledemic” – flu, COVID and RSV – as well as other respiratory infections.

BioVaxys Announces Allowance of DPX-Related Patent for Japan and Filing of Additional International Patent Applications

Retrieved on: 
Tuesday, March 5, 2024

This Patent was part of the extensive Intellectual Property portfolio recently acquired by BioVaxys from the former IMV, Inc.

Key Points: 
  • This Patent was part of the extensive Intellectual Property portfolio recently acquired by BioVaxys from the former IMV, Inc.
  • This Patent has already been issued in the US, and is currently pending in the EU.
  • BioVaxys also is pleased to announce it filed an international patent application through the Patent Cooperation Treaty ("PCT") from two pending patent applications in the US related to methods of formulating DPX™ compositions that comprise both a lipid-based adjuvant (i.e.
  • The PCT is a patent treaty with more than 150 member countries, makes it possible to seek patent protection for an invention simultaneously in a large number of countries by filing a single "international" patent application instead of filing several separate national or regional patent applications.